182 related articles for article (PubMed ID: 38006760)
61. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon
Tan J; Hu C; Deng P; Wan R; Cao L; Li M; Yang H; Gu Q; An J; Jiang J
Front Oncol; 2021; 11():646577. PubMed ID: 34513661
[TBL] [Abstract][Full Text] [Related]
62.
Xu H; Yang G; Liu R; Yang Y; Li W; Li J; Hao X; Xing P; Wang Y
Front Pharmacol; 2022; 13():976731. PubMed ID: 36188595
[No Abstract] [Full Text] [Related]
63. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
[TBL] [Abstract][Full Text] [Related]
64. Concomitant
Canale M; Petracci E; Delmonte A; Bronte G; Chiadini E; Ludovini V; Dubini A; Papi M; Baglivo S; De Luigi N; Verlicchi A; Chiari R; Landi L; Metro G; Burgio MA; Crinò L; Ulivi P
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32272775
[TBL] [Abstract][Full Text] [Related]
65. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
66. From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
Fukuda A; Okuma Y
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767589
[TBL] [Abstract][Full Text] [Related]
67. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in
Zhang Y; Zeng H; Qi C; Tan S; Huang Q; Pu X; Suda K; Santarpia M; Tian P; Li Y
Transl Lung Cancer Res; 2024 Apr; 13(4):875-884. PubMed ID: 38736500
[TBL] [Abstract][Full Text] [Related]
69. Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Zhang B; Xu J; Zhang X; Gu P; Wang H; Wang S; Qian J; Qiao R; Zhang Y; Yang W; Qian F; Zhou Y; Lu J; Zhang L; Han B
Lung Cancer; 2018 Mar; 117():27-31. PubMed ID: 29496252
[TBL] [Abstract][Full Text] [Related]
70. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
[TBL] [Abstract][Full Text] [Related]
71. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
72. Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.
Hu M; Zhang B; Xu J; Wang S; Zhao Y; Zhang L; Han B
Mol Diagn Ther; 2019 Dec; 23(6):773-779. PubMed ID: 31713818
[TBL] [Abstract][Full Text] [Related]
73. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
74. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
Hou H; Qin K; Liang Y; Zhang C; Liu D; Jiang H; Liu K; Zhu J; Lv H; Li T; Zhang X
Cancer Manag Res; 2019; 11():5665-5675. PubMed ID: 31417310
[No Abstract] [Full Text] [Related]
75. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis.
Kitadai R; Okuma Y
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626123
[TBL] [Abstract][Full Text] [Related]
76. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.
Li L
Heliyon; 2022 Sep; 8(9):e10407. PubMed ID: 36119883
[TBL] [Abstract][Full Text] [Related]
77. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
[TBL] [Abstract][Full Text] [Related]
78. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients.
Pluzanski A; Krzakowski M; Kowalski D; Dziadziuszko R
ESMO Open; 2020 Nov; 5(6):e001011. PubMed ID: 33148621
[TBL] [Abstract][Full Text] [Related]
79. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
Zhang Y; Wang Z; Hao X; Hu X; Wang H; Wang Y; Ying J
Chin J Cancer Res; 2017 Feb; 29(1):18-24. PubMed ID: 28373750
[TBL] [Abstract][Full Text] [Related]
80. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
